Company news
TransCode Therapeutics, Inc. news in 2022
TransCode Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
December 28, 2022
TransCode Therapeutics Announces Withdrawal of Registration Statement
December 5, 2022
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
November 29, 2022
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
November 13, 2022
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
November 8, 2022
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
October 25, 2022
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
October 12, 2022
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
August 14, 2022
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
August 1, 2022
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
July 10, 2022
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
May 31, 2022
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
May 18, 2022
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
May 15, 2022
TransCode Therapeutics Reports 2021 Results; Provides Business Update
March 30, 2022